Clinical Trial Update: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu [Phase 1]

View source ↗

Summary

A Phase 1 trial tested the combination of Interleukin-12 and trastuzumab in HER2/Neu-overexpressing cancers and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Breast Cancer
• Gastric Cancer
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Epithelial Cancer
• Pancreatic Cancer
• Prostate Cancer

Drugs mentioned

• Interleukin-12 (interleukin-12)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Status: COMPLETED